Our Standards: The Thomson Reuters Trust Principles. 1:18-cv-00823įor Par: Brian Farnan of Farnan and Martin Black of Dechertįor Eagle: David Moore and Bindu Palapura of Potter Anderson & Corroon and Bryan Hales and Jay Lefkowitz of Kirkland & Ellis District Court for the District of Delaware, No. Parent company Endo sold over 785 million of Vasostrict last year Infringement claims against Amneal still pending (Reuters) - Eagle Pharmaceuticals Inc's proposed generic of Endo. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product outside the United States. ![]() Par's infringement case against Amneal Pharmaceuticals Inc, which proposed its own generic of Vasostrict and was also part of the July bench trial, is still pending. This product information is intended for U.S. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. ![]() "Accordingly, the ANDA product Eagle is asking the FDA to approve cannot have" a pH in Par's patented range, and "therefore a judgment of noninfringement must necessarily ensue," Connolly said. provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Eagle asserted in its ANDA that its drug would have a lower pH value than outlined in Par's patents "through the entirety of the products' shelf lives," and it must comply with its ANDA specifications to receive FDA approval, the court said. The measurements for Eagle's product didn't show a "steady and inevitable creep" toward higher pH values, but "minor fluctuations" with no "discernible trend," Connolly said.Ĭonnolly also said Par mischaracterized the high end of Eagle's proposed pH range. "But the data do not establish that Eagle's ANDA product has the 'drift problem' Par claims," Connolly said in his Tuesday ruling. ![]() Par said the pH of Eagle's generic tends to drift upwards and that its proposal outlines a drug that is just below the patented range, making it likely to infringe.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |